Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?

被引：6
|
作者：
Remon, Jordi [1 ]
Hendriks, Lizza [2 ]
Aspeslagh, Sandrine [3 ]
Besse, Benjamin [4 ,5 ]
机构：
[1] HM Delfos, Ctr Integral Oncol Clara Campal Barcelona, Med Oncol Dept, Barcelona, Spain
[2] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Pulm Dis Dept, Maastricht, Netherlands
[3] UZ Brussels VUB, Dept Med Oncol, Brussels, Belgium
[4] Gustave Roussy, Dept Canc Med, Villejuif, France
[5] Univ Paris Saclay, Orsay, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
LUNG-CANCER; EFFICACY; SAFETY;
D O I：
10.1016/j.jtho.2019.07.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1701 / 1703
页数：3
相关论文
共 50 条
  • [21] The safety and efficacy of immune-checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseases
    Wu, Chunlan
    Zhong, Li
    Wu, Qing
    Lin, Shaowei
    Xie, Xianhe
    IMMUNOTHERAPY, 2021, 13 (06) : 527 - 540
  • [22] TOXICITIES OF SINGLE AGENT AND COMBINATION IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PRE-EXISTING AUTOIMMUNE DISEASES
    Sandigursky, Sabina
    Houssein, Safa
    Pundole, Xerxes
    Efuni, Elizaveta
    Cytryn, Samuel
    Buni, Maryam
    Pavlick, Anna
    Krogsgaard, Michelle
    Saberian, Chantal
    Altan, Mehmet
    Suarez-Almazor, Maria
    Weber, Jeffrey
    Diab, Adi
    Abdel-Wahab, Noha
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A395 - A395
  • [23] Antibiotic Exposure and Immune Checkpoint Inhibitors in Patients With NSCLC: The Backbone Matters
    Cortellini, Alessio
    Facchinetti, Francesco
    Derosa, Lisa
    Pinato, David J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (06) : 739 - 741
  • [24] Treatment-Free Survival in Advanced NSCLC Patients who Terminated Immune-Checkpoint Inhibitors.
    Nagai, T.
    Akamatsu, H.
    Takase, E.
    Murakami, E.
    Sugimoto, T.
    Shibaki, R.
    Hayata, A.
    Shimizu, T.
    Nakanishi, M.
    Koh, Y.
    Yamamoto, N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S404 - S405
  • [25] Safety of immune checkpoint inhibitors in patients with preexisting autoimmune disorders.
    Kumar, Rohit
    Chan, Abigail Sy
    Bandikatla, Sudeepthi
    Mudra, Sarah
    Ranjan, Smita
    Ngo, Phuong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders
    Coureau, Michelle
    Meert, Anne-Pascale
    Berghmans, Thierry
    Grigoriu, Bogdan
    FRONTIERS IN MEDICINE, 2020, 7
  • [27] Immune checkpoint inhibitors may be safe for patients with preexisting autoimmune disease
    Fillon, Mike
    CA-A CANCER JOURNAL FOR CLINICIANS, 2020, 70 (01) : 3 - 4
  • [28] Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy
    Le, Jiayuan
    Sun, Yuming
    Deng, Guangtong
    Dian, Yating
    Xie, Yanli
    Zeng, Furong
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2025, 21 (01)
  • [29] Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors
    Tocut, Milena
    Brenner, Ronen
    Zandman-Goddard, Gisele
    AUTOIMMUNITY REVIEWS, 2018, 17 (06) : 610 - 616
  • [30] Is it possible to use immune checkpoint inhibitors in patients with autoimmune or inflammatory disease?
    Danlos, Francois-Xavier
    Lambotte, Olivier
    M S-MEDECINE SCIENCES, 2018, 34 (6-7): : 516 - 518
12345